Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698033 | 0.91 | HSD11B1 (0.39) | ALDH1A1NPSR1HPGDMAPK1HSD11B1 | |
| SCHEMBL18377916 | 0.72 | — | — | |
| SCHEMBL24768423 | 0.68 | HSD11B1 (0.34) | HSD11B1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2616420 | 0.67 | ALDH1A1 (0.42) | ALDH1A1NPSR1HPGDMAPK1 | |
| SCHEMBL15069885 | 0.67 | MAPK13 (0.40) | HSD11B1 | |
| SCHEMBL10226038 | 0.66 | ALDH1A1 (0.41) | ALDH1A1NPSR1HPGDMAPK1HSD11B1 | |
| SCHEMBL9944598 | 0.66 | ALDH1A1 (0.41) | ALDH1A1NPSR1HPGDMAPK1 | |
| SCHEMBL25857280 | 0.65 | HSP90AA1 (0.40) | HSD11B1 | |
| SCHEMBL22952743 | 0.65 | PKM (0.42) | NPSR1 | |
| SCHEMBL19703329 | 0.64 | HSD11B1 (0.41) | ALDH1A1NPSR1HPGDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ALDH1A1 2149/4885NPSR1 3772/4885HPGD 864/4885 |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885NPSR1 994/4885HPGD 567/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | ALDH1A1 2149/4885NPSR1 3772/4885HPGD 864/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885NPSR1 994/4885HPGD 567/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ALDH1A1 2149/4885NPSR1 3772/4885HPGD 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.